SUSTAINED-RELEASE FORMULATION
    1.
    发明申请
    SUSTAINED-RELEASE FORMULATION 审中-公开
    持续发布公式

    公开(公告)号:US20130210742A1

    公开(公告)日:2013-08-15

    申请号:US13703596

    申请日:2011-06-23

    IPC分类号: A61K47/34

    摘要: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.

    摘要翻译: 本发明涉及包含重金属离子衍生物和重均分子量为约5,000至约40,000的乳酸聚合物或其盐的缓释制剂。 本发明的缓释制剂缓慢且稳定地释放长时间的化合物(I)或其盐,并且长时间地施加化合物(I)或其盐的药用作用。 此外,通过减少给药频率来提高患者便利性的本发明的缓释制剂是作为临床医学的优良配方。

    SUSTAINED-RELEASE FORMULATION
    2.
    发明申请
    SUSTAINED-RELEASE FORMULATION 审中-公开
    持续发布公式

    公开(公告)号:US20120302508A1

    公开(公告)日:2012-11-29

    申请号:US13517202

    申请日:2010-12-21

    IPC分类号: A61K38/08 A61P35/00

    CPC分类号: A61K9/1647 A61K9/0024

    摘要: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic acid-glycolic acid copolymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably release compound (I) or a salt thereof for a long time and exerts a medicinal effect of compound (I) or a salt thereof for a long time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing the number of administration times, is an excellent formulation as a clinical medicine.

    摘要翻译: 本发明涉及一种缓释制剂,其含有重均分子量为约5,000至约40,000的亚氨酸衍生物和乳酸 - 乙醇酸共聚物或其盐。 本发明的缓释制剂长时间缓慢稳定地释放化合物(I)或其盐,长时间发挥化合物(I)或其盐的药用作用。 此外,通过减少给药次数来提高患者便利性的本发明的缓释制剂是作为临床医学的优良配方。

    SUSTAINED-RELEASE MICROSPHERE CONTAINING SHORT CHAIN DEOXYRIBONUCLEIC ACID OR SHORT CHAIN RIBONUCLEIC ACID AND METHOD OF PRODUCING THE SAME
    3.
    发明申请
    SUSTAINED-RELEASE MICROSPHERE CONTAINING SHORT CHAIN DEOXYRIBONUCLEIC ACID OR SHORT CHAIN RIBONUCLEIC ACID AND METHOD OF PRODUCING THE SAME 审中-公开
    含有短链脱氨基酸或短链核糖核酸的保持性释放微球及其生产方法

    公开(公告)号:US20100310670A1

    公开(公告)日:2010-12-09

    申请号:US12065255

    申请日:2006-03-03

    摘要: A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid as an active ingredient, which has improved sustained-release properties and long-lasting efficacy, is provided. A fine particle formulation, encapsulating stably a short chain deoxyribonucleic acid or a short chain ribonucleic acid, being capable of inhibiting, for a long period, expression of a specific protein related to a disease, and which can be administered by injection or transmucosally, and a production method of the same are provided. A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid, particularly siRNA, as an active ingredient, especially a sustained-release microsphere prepared through a w1/o/w2 type emulsion, is characterized in that a positively charged basic substance, such as arginine, polyethylenimine, a cell permeable peptide, poly-L-lysine or poly-L-ornithine, is included in an in vivo degradable polymer.

    摘要翻译: 提供了含有短链脱氧核糖核酸或短链核糖核酸作为活性成分的持续释放微球制剂,其具有改善的持续释放性能和持久功效。 能够稳定地包封短链脱氧核糖核酸或短链核糖核酸的微粒制剂能够长时间地抑制与疾病相关的特异性蛋白质的表达,并且可以通过注射或经粘膜施用,以及 提供了其制造方法。 含有短链脱氧核糖核酸或短链核糖核酸,特别是siRNA作为活性成分,特别是通过w1 / o / w2型乳剂制备的持续释放微球的缓释微球制剂的特征在于: 带电的碱性物质,例如精氨酸,聚乙烯亚胺,细胞可渗透肽,聚-L-赖氨酸或聚-L-鸟氨酸,被包括在体内可降解的聚合物中。